Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and pRb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy

Journal of Neuro-Oncology

Volumn 46, Issue 1, 2000, Pages 71-80

  Kirla, Ruut ^a   Salminen, Eeva ^a   Huhtala, Sakke ^b   Nuutinen, Joanne ^a   Talve, Lauri ^a   Haapasalo, Hannu ^c   Kalimo, Hannu ^a,d  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Astrocytoma; Immunohistochemistry; p16; p21; p53; pRb

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CELL CYCLE; CELL LABELING; CELL PROLIFERATION; DIAGNOSTIC VALUE; GENE EXPRESSION; HUMAN; IMMUNOREACTIVITY; PROGNOSIS;

ADULT; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0034036394     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006473320474     Document Type: Article

References (34)

1. Salminen E, Nuutinen J, Huhtala S: Multivariate analysis of prognostic factors in 106 patients with malignant glioma. Eur J Cancer 32: 1918-1923, 1996
2. Bleehen N, Stenning S: A medical research council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 64: 769-774, 1991
3. Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumors of the central nervous system. In: World Health Organization International Histological Classification of Tumors. Springer Verlag, Berlin, Heidelberg, 1993
4. James C, Olson J: Molecular genetics and molecular biology advances in brain tumors. Curr Opinion Onc 8: 188-195, 1996
5. Sallinen P, Haapasalo H, Visakorpi T, Helen PT, Rantala IS, Isola JJ, Helin HJ: Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 174: 275-282, 1994
6. Gerdes J, Li L, Schlueter C, Duchrow MC, Wohlenberg C, Gerlach C: Immunobiochemical and molecular biologic characterization of the cell proliferation associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867-873, 1991
7. Cattoretti G, Becker MHG, Key G, Duchrow M, Schluter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin-embedded sections. J Pathol 168: 357-363, 1992
8. Burger PC, Shibata T, Kleihues P: The use of monoclonal antibody Ki-67 in the identification of proliferating cells. Surg Pathol 10: 611-617, 1986
9. Geradts J, Kratzke R, Niehans G, Wohlenberg C, Gerlach C: Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK 4A in archival human solid tumors, correlation with retinoblastoma protein expression. Cancer Res 55: 6006-6011, 1995
10. Louis D: A molecular genetic model of astrocytoma histopathology. Brain Pathol 7: 755-764, 1997
11. Jen J, Harper J, Bigner S, Bigner D, Papadopoulos N, Markowitz S, Willson J, Kintzer K, Vogelstein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-6358, 1994
12. He J, Olson J, James C: Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 55: 4833-4836, 1995
13. Nishikawa R, Furnari F, Lin H, Arap W, Berger M, Cavenee W, Huang H-J: Loss of p16INK4 expression is frequent in high grade gliomas. Cancer Res 55: 1941-1945, 1995
14. Tsuzuki T, Tsunoda S, Sakaki T, Konishi N, Hiasa Y, Nakamura M: Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas. Cancer 78: 287-293, 1996
15. Perry A, Nobori T, Ru N, Anderl K, Borell T, Mohapatra G, Feuerstein B, Jenkins R, Carson D: Detection of p16 gene deletions in gliomas, a comparision of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol 56: 999-1008, 1997
16. Louis D: The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53: 11-21, 1994
17. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO: Prognostic indicators in a range of astrocytic tumors: an immunohistochemical study with Ki67 and p53 antibodies. J Neurol Neurosurg Psychiatry 59: 413-419, 1995
18. Zuber P, Hamou MF, de Tribolet N: Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery 22: 364-368, 1988
19. Haapasalo H, Isola J, Sallinen P, Kalimo H, Helin H, Rantala I: Aberrant p53 expression in astrocytic neoplasms of the brain, association with proliferation. Am J Pathol 142: 1347-1351, 1993
20. Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yamamoto S, Tamaki M, Hirakawa K: Prognostic significance of Ki-67 labelling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 77: 373-380, 1996
21. Hsu D, Louis D, Efird J, Hedley-Whyte E: Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 56: 857-865, 1997
22. Bögler O, Huang HJ, Kleihues P, Cavenee WK: The p53 gene and its role in human brain tumors. Glia 15: 308-327, 1995
23. von Deimling A, von Ammon K, Schoenfend D, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3: 19-26, 1993
24. Lang F, Miller D, Koslow M, Newcomb E: Pathways leading to glioblastoma multiforme, a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81: 427-436, 1994
25. Reifenberger J, Ring G, Gies U, Cobbers J, Obertrass J, An H, Niederacher D, Wechsler W, Reifenberger G: Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 55: 822-831, 1996
26. Kleihues P, Ohgaki H: Genetics of glioma progression and the definition of primary and secondary glioblastoma. Brain Pathol 7: 1131-1136, 1997
27. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually excusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-224, 1996
28. Louis D, von Deimling A, Chung R, Rubio M, Whaley J, Eibl R, Ohgaki H, Wiestler O, Thor A, Seizinger BR: Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52: 31-38, 1993
29. Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M, Miller DC: A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 3: 229-235, 1993
30. Moulton T, Samara G, Chung W, Yuan L, Desai R, Sisti M, Bruce J, Tycko B: MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 146: 613-619, 1995
31. Ueki K, Ono Y, Henson J, Efird J, von Deimling A, Louis D: CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150-153, 1996
32. Piva R, Cavalla P, Bortolotto S, Grosso R, Richiardi P, Dutto A, Schiffer D: CDKN2/p16 inactivation and p16 immunohistochemistry in astrocytic gliomas. Int J Oncol 12: 55-58, 1998
33. Nakamura M, Konishi M, Hiasa Y, Tsunoda S, Fukushima Y, Tsuzuki T, Takemura K, Aoki H, Kobitsu K, Sakaki T: Immunohistochemical detection of CDKN2, retinoblastoma and p53 gene products in primary astrocytic tumors. Int J Oncol 8: 889-893, 1996
34. Rao LS, Miller DC, Newcomb EW: Correlative immunohistochemistry and molecular genetic study of the inactivation of the p16INK4A genes in astrocytomas. Diagn Mol Pathol 6: 115-122, 1997